<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/1AB05DA1-4DD6-4843-B416-D7D9441EBFFB"><gtr:id>1AB05DA1-4DD6-4843-B416-D7D9441EBFFB</gtr:id><gtr:name>Royal Veterinary College</gtr:name><gtr:department>Pathology and Pathogen Biology</gtr:department><gtr:address><gtr:line1>Royal College Street</gtr:line1><gtr:line2>Camden Town</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW1 0TU</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1AB05DA1-4DD6-4843-B416-D7D9441EBFFB"><gtr:id>1AB05DA1-4DD6-4843-B416-D7D9441EBFFB</gtr:id><gtr:name>Royal Veterinary College</gtr:name><gtr:address><gtr:line1>Royal College Street</gtr:line1><gtr:line2>Camden Town</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW1 0TU</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD7CF537-B190-463E-90A6-2F7A9EFE8C72"><gtr:id>DD7CF537-B190-463E-90A6-2F7A9EFE8C72</gtr:id><gtr:name>Intervet UK Limited (Walton Manor)</gtr:name><gtr:address><gtr:line1>Walton Manor</gtr:line1><gtr:line3>Walton</gtr:line3><gtr:line4>Milton Keynes</gtr:line4><gtr:postCode>MK7 7AJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EA5A4D02-652E-45E3-8008-30EE9C158200"><gtr:id>EA5A4D02-652E-45E3-8008-30EE9C158200</gtr:id><gtr:firstName>Fiona</gtr:firstName><gtr:surname>Tomley</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0D8A8341-434B-4835-AFC1-19A077182C62"><gtr:id>0D8A8341-434B-4835-AFC1-19A077182C62</gtr:id><gtr:firstName>Damer</gtr:firstName><gtr:surname>Blake</gtr:surname><gtr:orcidId>0000-0003-1077-2306</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FH020195%2F2"><gtr:id>1D3E4879-8C7D-4602-8814-601C96D1379F</gtr:id><gtr:title>Recombinant vaccines for poultry: the use of attenuated Eimeria acervulina as a novel live delivery vehicle for viral vaccines</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/H020195/2</gtr:grantReference><gtr:abstractText>More than 50 billion chickens are produced each year in the world and control of infectious diseases is of primary concern to the poultry industry. Viral, bacterial and parasitic infections compromise the economics and efficiency of meat and egg production, cause severe animal welfare problems and in some cases have serious potential for infecting humans. Demand for effective, cheap vaccines against a broad panel of pathogens has never been higher, particularly set against the pressing needs of global food security. For many viral infections of poultry, we understand which parts of the virus are needed to induce strong protective immunity and could be in a good position to develop new kinds of recombinant 'vectored' vaccines that would be safe, cheap and effective. However the development of organisms that could be used as the vaccine delivery 'vectors' has so far seen commercialisation of only two based on fowlpox virus (FWPV) and herpes virus of turkeys (HVT). Both of these suffer some drawbacks, especially because they have to be given by individual scarification or injection and cannot be administered in a simpler way such as in drinking water or by aerosol spray over large numbers of chicks. Eimeria are host-specific protozoan parasites that transmit between birds by the faecal-oral route and rapidly establish acute intestinal infections that are self-limiting (7-14 days) and induce life-long protective immunity. In poultry they cause coccidiosis, one of the most globally important infections that afflicts the industry, causing severe losses unless controlled by chemotherapy or vaccination. Vaccines using laboratory-derived lines of live-attenuated Eimeria are given in the drinking water and are well established and very effective. The world-leading Eimeria vaccine is Paracox, manufactured by Intervet/Schering-Plough Animal Health, and this sells &amp;gt; 1 billion doses each year and has an exemplary record of safety and efficacy. In our lab we have recently developed methods that allow us to manipulate the genetic material of Eimeria parasites which means we can now make stable transgenic parasite lines; this means it is possible to try and develop Eimeria parasites as vaccine vectors for vaccinal antigens. Recombinant vaccines based on an Eimeria vector would have several advantages over existing vaccines. Because the parasites have large genomes it is likely that we will be able to insert and express vaccine antigens from several different organisms within a single parasite line so a single vaccine could protect against several diseases. These parasites are already licensed as live vaccines and are known to be extremely safe; they infect only chickens and they are completely cleared from the host by 14 days after vaccination. They are known to induce a broad range of potent immune responses so they are likely to be useful for inducing immunity to different kinds of pathogens (viruses, other parasites, bacteria). We propose to investigate the vaccine vector potential of an attenuated Eimeria parasite (E. acervulina HP, one of the Paracox parasites) using well characterised antigens from two important viruses of poultry. The first is infectious bursal disease virus (IBDV), which causes Gumboro, an immunosuppressive disease of poultry that poses severe problems in health and productivity and also interferes with the efficacy of vaccination programmes. IBDV is a particular problem in the broiler industry at the moment with new virulent and variant strains emerging that are able to break through existing vaccines. The second is infectious laryngotracheitis virus, a persistent problem particularly in breeding and commercial layer flocks and for which strong cellular immunity as well as antibody responses are required for effective control.</gtr:abstractText><gtr:technicalSummary>Chickens are the most numerous livestock species in the world. Industrial and political demand for effective, cheap vaccines against infectious diseases that can compromise poultry production, cause severe animal welfare problems and have serious potential for infecting humans has never been higher, particularly set against the pressing needs of global food security. Whilst immunoprotective antigens have been identified for many viral pathogens that infect poultry the commercial development of delivery vectors has been limited to fowlpox virus and a herpes virus of turkeys, both of which require invasive single bird treatment. The ability of Eimeria to induce potent life-long protective immunity after a single self-limiting, host-specific infection and the robust longevity of the oocyst phase of the lifecycle, combined with the recent development of stable transfection strategies for these parasites, promotes their use as novel vectors. Attenuated Eimeria parasites are already extensively used as anticoccidial vaccines. In partnership with Intervet/Schering-Plough Animal Health we propose to investigate the vector potential of Eimeria using Eimeria acervulina as a model to deliver well characterised antigens from two persistently problematic viruses of poultry, infectious bursal disease virus (IBDV) and infectious laryngotracheitis virus (ILTV). Transfection constructs developed for use with Eimeria tenella will be tested with E. acervulina and modified to express the vaccinal antigens IBDV VP2 or ILTV gB, supported by new next-generation derived genomic resources for the recipient. Constructs designed to control the site or timing of transgene expression will be developed and tested to identify the best combination on the basis of ability to induce host immune responses and provide protection against viral challenge. This project is expected to produce parasite lines suitable for use as new vaccines and data supporting the use of Eimeria as vaccine vectors.</gtr:technicalSummary><gtr:fund><gtr:end>2014-12-27</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2011-06-28</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>508310</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>CHF</gtr:currCode><gtr:currCountryCode>Switzerland</gtr:currCountryCode><gtr:currLang>it_CH</gtr:currLang><gtr:description>early post-doc mobility fellowshiop</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Swiss National Science Foundation</gtr:fundingOrg><gtr:id>03FE752C-398C-4BEE-865C-37A1A7368283</gtr:id><gtr:outcomeId>56dd8fd8356528.69455609</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>314000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Horizon 2020</gtr:department><gtr:description>Tackling losses from Terrestial Animal Diseases: PARAGONE</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>B870F309-6F64-424E-BBC5-0925509D67B8</gtr:id><gtr:outcomeId>56dd9074911aa4.59969620</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>8000</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Houghton Trust Small Grant Award (2016/2017)</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>The Houghton Trust</gtr:fundingOrg><gtr:id>C7CDBB2A-D8D3-4F20-89C2-B818610E5EAA</gtr:id><gtr:outcomeId>58c683adc4ac95.11879487</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>595000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Horizon 2020</gtr:department><gtr:description>Tackling Losses from Terrestirial Animal Diseases: SAPHIR</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>B0E66287-4BC6-4934-8E41-17699A57EEA1</gtr:id><gtr:outcomeId>56dd8dc7d90244.11411745</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400104</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Response mode highlight 'Vaccine'</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/P003931/1</gtr:fundingRef><gtr:id>1D3033AA-0192-4782-AD9B-882F071ABB0E</gtr:id><gtr:outcomeId>58bec8d52885d5.11423949</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>So far findings from this project have been used internally by the team and by our IPA partner but not more widely</gtr:description><gtr:id>2206E13E-F0EA-40EB-B6BD-63C6D49D631B</gtr:id><gtr:impactTypes/><gtr:outcomeId>54637e9a7cddd0.97873588</gtr:outcomeId><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We generated a series of populations of transgenic Eimeria tenella parasites that express three vaccine antigens derived from two viral pathogens of poultry (infectious bursal disease virus, IBDV; infectious laryngotracheitis virus, ILTV). For each of these targets we generated two populations which express a soluble version of the antigen, expressed at either a high or low level (relative to endogenous E. tenella antigens; data derived from RNAseq libraries) and two further populations that express secreted or GPI-anchored versions of the antigen, expressed at a high level. The methodology relies on the assembly of Eimeria-specific expression cassettes within a plasmid vector that co-expresses either mCitrine or mCherry fluorescent reporters also under control of an Eimeria-specific promoter. Individual plasmids were used to generate the transgenic parasite populations by nucleofection of the sporozoite stage in vitro using a restriction-enzyme mediated integration enhancement to promote high copy number integration at random sites. After passage through chickens, with enrichment for transgenic parasites by FACs sorting of offspring oocysts, populations were then sent to our industrial partner for testing immunogenicity and efficacy in vivo. 

Characterisation of the transgenic parasites and analysis of the potential of Eimeria parasites as novel vaccine vectors is now completed. Antigens were successfully expressed and we were able to demonstrate a low level of antibody responsiveness to viral antigens expressed as soluble, secreted or surface-tethered proteins within the parasites.</gtr:description><gtr:exploitationPathways>Applications are in the field of vaccinology and the potential use of a host-specific gut parasite for delivery of antigens to the chicken. Because of the work we have done in this grant, we were successful in securing funding to continue development of the vaccine vector through two H2020 consortium grants</gtr:exploitationPathways><gtr:id>A4401AE7-163D-4EED-A07B-2A8EB94CDF1A</gtr:id><gtr:outcomeId>5463844a077309.64686155</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Adapted methods for nucleofection of eimeria sporozoites to use smaller numbers of parasites, and be able to select transgenic parasite populations rapidly by FACs analysis of output oocysts.</gtr:description><gtr:id>19A7B393-AC3D-4E87-8C36-222B23892C0E</gtr:id><gtr:impact>Allows for more rapid screening of candidate vaccines (expressed in the Eimeria vector platform) in both in vitro (cell culture) and in vivo (chickens). This improved methodology is now being exploited in two H2020 projects, funded within our lab. Publication on the methodology is 
in preparation.</gtr:impact><gtr:outcomeId>56dd921f4db6d6.07709956</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Improvement to transfection technology for Eimeria species</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Protocols specific for the passage, purification and manipulation of Eimeria parasites were introduced to TANUVAS, Chennai and IVRI, Bareilly. Development and validation of methods for this project at TANUVAS, IVRI and RVC yielded a comprehensive protocol describing sample collection, preparation and diagnostic analysis for use with EImeria (for the first time). Protocols specific to the development of attenuated vaccines using local parasite strains and to culture of E. tenella in embryonic chicks and cell culture were provided to TANUVAS in support of parallel projects.</gtr:description><gtr:id>D30EDA5C-DCA3-4595-97A2-25426738CC0E</gtr:id><gtr:impact>Support and expansion of parasitology research at TANUVAS and IVRI; provision of robust sampling methods for parasite surveillance activities; publication of several papers in local and international journals</gtr:impact><gtr:outcomeId>546247778c4232.95016851</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Laboratory protocols for Eimeria</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B2C0C645-6B2F-4700-BBB8-0E10E92B119F</gtr:id><gtr:title>A selective review of advances in coccidiosis research.</gtr:title><gtr:parentPublicationTitle>Advances in parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a0038f9c6ee77cdf4822d85e5e9f903"><gtr:id>2a0038f9c6ee77cdf4822d85e5e9f903</gtr:id><gtr:otherNames>Chapman HD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0065-308X</gtr:issn><gtr:outcomeId>5437f7104c4c59.18556608</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCEC3789-10EF-4236-AE81-9F4141F33140</gtr:id><gtr:title>Securing poultry production from the ever-present Eimeria challenge.</gtr:title><gtr:parentPublicationTitle>Trends in parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0be00afcb59af2006353786c22c5b855"><gtr:id>0be00afcb59af2006353786c22c5b855</gtr:id><gtr:otherNames>Blake DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-4922</gtr:issn><gtr:outcomeId>5437f70fcb9105.21668611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5C5E950-66BA-4E5B-8190-8284151909E0</gtr:id><gtr:title>Recombinant anticoccidial vaccines - a cup half full?</gtr:title><gtr:parentPublicationTitle>Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0be00afcb59af2006353786c22c5b855"><gtr:id>0be00afcb59af2006353786c22c5b855</gtr:id><gtr:otherNames>Blake DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1567-1348</gtr:issn><gtr:outcomeId>5a900141113f08.70558825</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33933D3F-2A99-4932-9E87-A7EEBF931AA2</gtr:id><gtr:title>Eimeria species parasites as novel vaccine delivery vectors: anti-Campylobacter jejuni protective immunity induced by Eimeria tenella-delivered CjaA.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b263ebd9ddd2865e9d7ff705c74a19db"><gtr:id>b263ebd9ddd2865e9d7ff705c74a19db</gtr:id><gtr:otherNames>Clark JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5437f711cc8d51.54654348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02808E63-A3EA-4349-9A5C-2EC59DFEF76A</gtr:id><gtr:title>Are Eimeria Genetically Diverse, and Does It Matter?</gtr:title><gtr:parentPublicationTitle>Trends in parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b27ff50d0bfaf49d2437a6da8c0342d6"><gtr:id>b27ff50d0bfaf49d2437a6da8c0342d6</gtr:id><gtr:otherNames>Clark EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-4922</gtr:issn><gtr:outcomeId>58bebb517adb89.09617839</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F6E934C-8CD7-4271-A927-D6725C5B7364</gtr:id><gtr:title>Viral proteins expressed in the protozoan parasite Eimeria tenella are detected by the chicken immune system.</gtr:title><gtr:parentPublicationTitle>Parasites &amp; vectors</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a09878c98afc9abfe16f31f16e66213"><gtr:id>7a09878c98afc9abfe16f31f16e66213</gtr:id><gtr:otherNames>Marugan-Hernandez V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-3305</gtr:issn><gtr:outcomeId>58bebb51b936e4.46100510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6402D840-1E03-4FBB-824D-95CCEEC8B78C</gtr:id><gtr:title>Eimeria tenella protein trafficking: differential regulation of secretion versus surface tethering during the life cycle.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a09878c98afc9abfe16f31f16e66213"><gtr:id>7a09878c98afc9abfe16f31f16e66213</gtr:id><gtr:otherNames>Marugan-Hernandez V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa84120a988c8.53212981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4829A2E-0226-4632-B200-A7578755A1F0</gtr:id><gtr:title>Development of vaccines for parasitic diseases of animals: Challenges and opportunities.</gtr:title><gtr:parentPublicationTitle>Parasite immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e0e1e80d01157eda1206b73a6016c30"><gtr:id>7e0e1e80d01157eda1206b73a6016c30</gtr:id><gtr:otherNames>Morrison WI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0141-9838</gtr:issn><gtr:outcomeId>58bebb514926d7.78938423</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A457B94-68A1-4615-985C-A84E331E8960</gtr:id><gtr:title>Population, genetic, and antigenic diversity of the apicomplexan Eimeria tenella and their relevance to vaccine development.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0be00afcb59af2006353786c22c5b855"><gtr:id>0be00afcb59af2006353786c22c5b855</gtr:id><gtr:otherNames>Blake DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>56dd8b13477c39.95110387</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/H020195/2</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>